Cargando…
Identification of Cell Type-Specific Differences in Erythropoietin Receptor Signaling in Primary Erythroid and Lung Cancer Cells
Lung cancer, with its most prevalent form non-small-cell lung carcinoma (NSCLC), is one of the leading causes of cancer-related deaths worldwide, and is commonly treated with chemotherapeutic drugs such as cisplatin. Lung cancer patients frequently suffer from chemotherapy-induced anemia, which can...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4975441/ https://www.ncbi.nlm.nih.gov/pubmed/27494133 http://dx.doi.org/10.1371/journal.pcbi.1005049 |
_version_ | 1782446726487998464 |
---|---|
author | Merkle, Ruth Steiert, Bernhard Salopiata, Florian Depner, Sofia Raue, Andreas Iwamoto, Nao Schelker, Max Hass, Helge Wäsch, Marvin Böhm, Martin E. Mücke, Oliver Lipka, Daniel B. Plass, Christoph Lehmann, Wolf D. Kreutz, Clemens Timmer, Jens Schilling, Marcel Klingmüller, Ursula |
author_facet | Merkle, Ruth Steiert, Bernhard Salopiata, Florian Depner, Sofia Raue, Andreas Iwamoto, Nao Schelker, Max Hass, Helge Wäsch, Marvin Böhm, Martin E. Mücke, Oliver Lipka, Daniel B. Plass, Christoph Lehmann, Wolf D. Kreutz, Clemens Timmer, Jens Schilling, Marcel Klingmüller, Ursula |
author_sort | Merkle, Ruth |
collection | PubMed |
description | Lung cancer, with its most prevalent form non-small-cell lung carcinoma (NSCLC), is one of the leading causes of cancer-related deaths worldwide, and is commonly treated with chemotherapeutic drugs such as cisplatin. Lung cancer patients frequently suffer from chemotherapy-induced anemia, which can be treated with erythropoietin (EPO). However, studies have indicated that EPO not only promotes erythropoiesis in hematopoietic cells, but may also enhance survival of NSCLC cells. Here, we verified that the NSCLC cell line H838 expresses functional erythropoietin receptors (EPOR) and that treatment with EPO reduces cisplatin-induced apoptosis. To pinpoint differences in EPO-induced survival signaling in erythroid progenitor cells (CFU-E, colony forming unit-erythroid) and H838 cells, we combined mathematical modeling with a method for feature selection, the L(1) regularization. Utilizing an example model and simulated data, we demonstrated that this approach enables the accurate identification and quantification of cell type-specific parameters. We applied our strategy to quantitative time-resolved data of EPO-induced JAK/STAT signaling generated by quantitative immunoblotting, mass spectrometry and quantitative real-time PCR (qRT-PCR) in CFU-E and H838 cells as well as H838 cells overexpressing human EPOR (H838-HA-hEPOR). The established parsimonious mathematical model was able to simultaneously describe the data sets of CFU-E, H838 and H838-HA-hEPOR cells. Seven cell type-specific parameters were identified that included for example parameters for nuclear translocation of STAT5 and target gene induction. Cell type-specific differences in target gene induction were experimentally validated by qRT-PCR experiments. The systematic identification of pathway differences and sensitivities of EPOR signaling in CFU-E and H838 cells revealed potential targets for intervention to selectively inhibit EPO-induced signaling in the tumor cells but leave the responses in erythroid progenitor cells unaffected. Thus, the proposed modeling strategy can be employed as a general procedure to identify cell type-specific parameters and to recommend treatment strategies for the selective targeting of specific cell types. |
format | Online Article Text |
id | pubmed-4975441 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-49754412016-08-25 Identification of Cell Type-Specific Differences in Erythropoietin Receptor Signaling in Primary Erythroid and Lung Cancer Cells Merkle, Ruth Steiert, Bernhard Salopiata, Florian Depner, Sofia Raue, Andreas Iwamoto, Nao Schelker, Max Hass, Helge Wäsch, Marvin Böhm, Martin E. Mücke, Oliver Lipka, Daniel B. Plass, Christoph Lehmann, Wolf D. Kreutz, Clemens Timmer, Jens Schilling, Marcel Klingmüller, Ursula PLoS Comput Biol Research Article Lung cancer, with its most prevalent form non-small-cell lung carcinoma (NSCLC), is one of the leading causes of cancer-related deaths worldwide, and is commonly treated with chemotherapeutic drugs such as cisplatin. Lung cancer patients frequently suffer from chemotherapy-induced anemia, which can be treated with erythropoietin (EPO). However, studies have indicated that EPO not only promotes erythropoiesis in hematopoietic cells, but may also enhance survival of NSCLC cells. Here, we verified that the NSCLC cell line H838 expresses functional erythropoietin receptors (EPOR) and that treatment with EPO reduces cisplatin-induced apoptosis. To pinpoint differences in EPO-induced survival signaling in erythroid progenitor cells (CFU-E, colony forming unit-erythroid) and H838 cells, we combined mathematical modeling with a method for feature selection, the L(1) regularization. Utilizing an example model and simulated data, we demonstrated that this approach enables the accurate identification and quantification of cell type-specific parameters. We applied our strategy to quantitative time-resolved data of EPO-induced JAK/STAT signaling generated by quantitative immunoblotting, mass spectrometry and quantitative real-time PCR (qRT-PCR) in CFU-E and H838 cells as well as H838 cells overexpressing human EPOR (H838-HA-hEPOR). The established parsimonious mathematical model was able to simultaneously describe the data sets of CFU-E, H838 and H838-HA-hEPOR cells. Seven cell type-specific parameters were identified that included for example parameters for nuclear translocation of STAT5 and target gene induction. Cell type-specific differences in target gene induction were experimentally validated by qRT-PCR experiments. The systematic identification of pathway differences and sensitivities of EPOR signaling in CFU-E and H838 cells revealed potential targets for intervention to selectively inhibit EPO-induced signaling in the tumor cells but leave the responses in erythroid progenitor cells unaffected. Thus, the proposed modeling strategy can be employed as a general procedure to identify cell type-specific parameters and to recommend treatment strategies for the selective targeting of specific cell types. Public Library of Science 2016-08-05 /pmc/articles/PMC4975441/ /pubmed/27494133 http://dx.doi.org/10.1371/journal.pcbi.1005049 Text en © 2016 Merkle et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Merkle, Ruth Steiert, Bernhard Salopiata, Florian Depner, Sofia Raue, Andreas Iwamoto, Nao Schelker, Max Hass, Helge Wäsch, Marvin Böhm, Martin E. Mücke, Oliver Lipka, Daniel B. Plass, Christoph Lehmann, Wolf D. Kreutz, Clemens Timmer, Jens Schilling, Marcel Klingmüller, Ursula Identification of Cell Type-Specific Differences in Erythropoietin Receptor Signaling in Primary Erythroid and Lung Cancer Cells |
title | Identification of Cell Type-Specific Differences in Erythropoietin Receptor Signaling in Primary Erythroid and Lung Cancer Cells |
title_full | Identification of Cell Type-Specific Differences in Erythropoietin Receptor Signaling in Primary Erythroid and Lung Cancer Cells |
title_fullStr | Identification of Cell Type-Specific Differences in Erythropoietin Receptor Signaling in Primary Erythroid and Lung Cancer Cells |
title_full_unstemmed | Identification of Cell Type-Specific Differences in Erythropoietin Receptor Signaling in Primary Erythroid and Lung Cancer Cells |
title_short | Identification of Cell Type-Specific Differences in Erythropoietin Receptor Signaling in Primary Erythroid and Lung Cancer Cells |
title_sort | identification of cell type-specific differences in erythropoietin receptor signaling in primary erythroid and lung cancer cells |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4975441/ https://www.ncbi.nlm.nih.gov/pubmed/27494133 http://dx.doi.org/10.1371/journal.pcbi.1005049 |
work_keys_str_mv | AT merkleruth identificationofcelltypespecificdifferencesinerythropoietinreceptorsignalinginprimaryerythroidandlungcancercells AT steiertbernhard identificationofcelltypespecificdifferencesinerythropoietinreceptorsignalinginprimaryerythroidandlungcancercells AT salopiataflorian identificationofcelltypespecificdifferencesinerythropoietinreceptorsignalinginprimaryerythroidandlungcancercells AT depnersofia identificationofcelltypespecificdifferencesinerythropoietinreceptorsignalinginprimaryerythroidandlungcancercells AT raueandreas identificationofcelltypespecificdifferencesinerythropoietinreceptorsignalinginprimaryerythroidandlungcancercells AT iwamotonao identificationofcelltypespecificdifferencesinerythropoietinreceptorsignalinginprimaryerythroidandlungcancercells AT schelkermax identificationofcelltypespecificdifferencesinerythropoietinreceptorsignalinginprimaryerythroidandlungcancercells AT hasshelge identificationofcelltypespecificdifferencesinerythropoietinreceptorsignalinginprimaryerythroidandlungcancercells AT waschmarvin identificationofcelltypespecificdifferencesinerythropoietinreceptorsignalinginprimaryerythroidandlungcancercells AT bohmmartine identificationofcelltypespecificdifferencesinerythropoietinreceptorsignalinginprimaryerythroidandlungcancercells AT muckeoliver identificationofcelltypespecificdifferencesinerythropoietinreceptorsignalinginprimaryerythroidandlungcancercells AT lipkadanielb identificationofcelltypespecificdifferencesinerythropoietinreceptorsignalinginprimaryerythroidandlungcancercells AT plasschristoph identificationofcelltypespecificdifferencesinerythropoietinreceptorsignalinginprimaryerythroidandlungcancercells AT lehmannwolfd identificationofcelltypespecificdifferencesinerythropoietinreceptorsignalinginprimaryerythroidandlungcancercells AT kreutzclemens identificationofcelltypespecificdifferencesinerythropoietinreceptorsignalinginprimaryerythroidandlungcancercells AT timmerjens identificationofcelltypespecificdifferencesinerythropoietinreceptorsignalinginprimaryerythroidandlungcancercells AT schillingmarcel identificationofcelltypespecificdifferencesinerythropoietinreceptorsignalinginprimaryerythroidandlungcancercells AT klingmullerursula identificationofcelltypespecificdifferencesinerythropoietinreceptorsignalinginprimaryerythroidandlungcancercells |